Interferon Gamma Counteracts the Angiogenic Switch and Induces Vascular Permeability in Dextran Sulfate Sodium Colitis in Mice

Inflammatory Bowel Diseases

Volumn 21, Issue 10, 2015, Pages 2360-2371

  Haep, Lisa ^a   Britzen Laurent, Nathalie ^a   Weber, Thomas G ^b   Naschberger, Elisabeth ^a   Schaefer, Alexander ^a   Kremmer, Elisabeth ^c   Foersch, Sebastian ^a   Vieth, Michael ^d   Scheuer, Werner ^b   Wirtz, Stefan ^a   Waldner, Maximilian ^a   Stürzl, Michael ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

angiogenesis; IBD; interferon

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN 1; MESSENGER RNA; UNCLASSIFIED DRUG; DEXTRAN SULFATE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CAPILLARY DENSITY; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VIVO STUDY; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; BIOPSY; BLOOD VESSEL; C57BL MOUSE; CAPILLARY PERMEABILITY; CHEMICALLY INDUCED; COLITIS; COLON; DISEASE MODEL; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NORMAL HUMAN; PATHOLOGY; VASCULAR REMODELING; VASCULARIZATION;

ANIMALS; BIOPSY; BLOOD VESSELS; CAPILLARY PERMEABILITY; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; GTP-BINDING PROTEINS; HEALTHY VOLUNTEERS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; VASCULAR REMODELING;

EID: 84942245794     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000490     Document Type: Article

References (40)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126:1504-1517.
2. Cromer WE, Mathis JM, Granger DN, et al. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol. 2011;17:578-593.
3. Funderburg NT, Stubblefield Park SR, Sung HC, et al. Circulating CD4+ and CD8+ T cells are activated in IBD and are associated with plasma markers of inflammation. Immunology. 2013;140:87-97.
4. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91-99.
5. Chidlow JH Jr, Langston W, Greer JJ, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol. 2006;169:2014-2030.
6. Cromer WE, Ganta CV, Patel M, et al. VEGF-A isoform modulation in an preclinical TNBS model of ulcerative colitis: protective effects of a VEGF164b therapy. J Transl Med. 2013;11:207.
7. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2009;136:585-595.e585.
8. Hindryckx P, Waeytens A, Laukens D, et al. Absence of placental growth factor blocks dextran sodium sulfate-induced colonic mucosal angiogenesis, increases mucosal hypoxia and aggravates acute colonic injury. Lab Invest. 2010;90:566-576.
9. Ito R, Shin-Ya M, Kishida T, et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 2006;146:330-338.
10. Oshima T, Laroux FS, Coe LL, et al. Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvasc Res. 2001;61:130-143.
11. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329-342.
12. Guenzi E, Topolt K, Cornali E, et al. The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. EMBO J. 2001;20:5568-5577.
13. Guenzi E, Topolt K, Lubeseder-Martellato C, et al. The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J. 2003;22: 3772-3782.
14. Weinlander K, Naschberger E, Lehmann MH, et al. Guanylate binding protein-1 inhibits spreading and migration of endothelial cells through induction of integrin alpha4 expression. FASEB J. 2008;22:4168-4178.
15. Grenz S, Naschberger E, Merkel S, et al. IFN-gamma-driven intratumoral microenvironment exhibits superior prognostic effect compared with an IFN-alpha-driven microenvironment in patients with colon carcinoma. Am J Pathol. 2013;183:1897-1909.
16. Lubeseder-Martellato C, Guenzi E, Jorg A, et al. Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. Am J Pathol. 2002;161:1749-1759.
17. Naschberger E, Croner RS, Merkel S, et al. Angiostatic immune reaction in colorectal carcinoma: impact on survival and perspectives for antiangiogenic therapy. Int J Cancer. 2008;123:2120-2129.
18. Naschberger E, Wenzel J, Kretz CC, et al. Increased expression of guanylate binding protein-1 in lesional skin of patients with cutaneous lupus erythematosus. Exp Dermatol. 2011;20:102-106.
19. Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-546.
20. Waldner MJ, Wirtz S, Neufert C, et al. Confocal laser endomicroscopy and narrow-band imaging-aided endoscopy for in vivo imaging of colitis and colon cancer in mice. Nat Protoc. 2011;6:1471-1481.
21. Poschinger T, Renner A, Eisa F, et al. Dynamic contrast-enhanced microcomputed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts. Invest Radiol. 2014;49:445-456.
22. Britzen-Laurent N, Lipnik K, Ocker M, et al. GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis. 2013;34:153-162.
23. Ostalecki C, Konrad A, Thurau E, et al. Combined multi-gene analysis at the RNA and protein levels in single FFPE tissue sections. Exp Mol Pathol. 2013;95:1-6.
24. Sturzl M, Roth WK, Brockmeyer NH, et al. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci USA. 1992;89:7046-7050.
25. Kuhn E, Naschberger E, Konrad A, et al. A novel chip-based parallel transfection assay to evaluate paracrine cell interactions. Lab Chip. 2012;12:1363-1372.
26. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler Thromb Vasc Biol. 1997;17:1193-1202.
27. Lienau J, Schmidt-Bleek K, Peters A, et al. Differential regulation of blood vessel formation between standard and delayed bone healing. J Orthop Res. 2009;27:1133-1140.
28. Zanetta L, Marcus SG, Vasile J, et al. Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. Int J Cancer. 2000;85:281-288.
29. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001;96: 822-828.
30. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298-307.
31. Rauch I, Muller M, Decker T. The regulation of inflammation by interferons and their STATs. JAKSTAT. 2013;2:e23820.
32. Naschberger E, Werner T, Vicente AB, et al. Nuclear factor-kappaB motif and interferon-alpha-stimulated response element co-operate in the activation of guanylate-binding protein-1 expression by inflammatory cytokines in endothelial cells. Biochem J. 2004;379:409-420.
33. Tolstanova G, Deng X, French SW, et al. Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice. Lab Invest. 2012;92:9-21.
34. Jaczewska J, Abdulreda MH, Yau CY, et al. TNF-alpha and IFN-gamma promote lymphocyte adhesion to endothelial junctional regions facilitating transendothelial migration. J Leukoc Biol. 2014;95:265-274.
35. Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol. 2003;171:6164-6172.
36. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut. 2006; 55:1131-1137.
37. Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut. 2006;55:1138-1144.
38. Camoglio L, te Velde AA, de Boer A, et al. Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-gamma receptor-deficient mice. Eur J Immunol. 2000;30:1486-1495.
39. Knod JL, Crawford K, Dusing M, et al. Mouse strain influences angiogenic response to dextran sodium sulfate-induced colitis. J Surg Res. 2014;190:47-54.
40. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24-30.